Caplacizumab structure
|
Common Name | Caplacizumab | ||
|---|---|---|---|---|
| CAS Number | 915810-67-2 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of CaplacizumabCaplacizumab (Cablivi) is a humanized anti-von Willebrand factor (vWF) nanobody. Caplacizumab inhibits the vWF-mediated platelet adhesion and prevents further microthrombi formation. Caplacizumab can be used for the research of thrombotic thrombocytopenic purpura (TTP)[1]. |
| Name | Caplacizumab |
|---|
| Description | Caplacizumab (Cablivi) is a humanized anti-von Willebrand factor (vWF) nanobody. Caplacizumab inhibits the vWF-mediated platelet adhesion and prevents further microthrombi formation. Caplacizumab can be used for the research of thrombotic thrombocytopenic purpura (TTP)[1]. |
|---|---|
| Related Catalog | |
| References |
| No Any Chemical & Physical Properties |